Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis, World Journal of Surgical Oncology

Cancers, Free Full-Text

Ipilimumab (Yervoy) Drug Information

Advances in targeted therapy and immunotherapy for melanoma (Review)

Full article: Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients

Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study - European Journal of Cancer

First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations - ScienceDirect

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Rationale for combining ipilimumab and nivolumab. CTLA-4: Cytotoxic

Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma - Southern Iowa Mental Health Center